Treatment innovations for pancreatic adenocarcinoma Jan. 27, 2020 Overview Show transcript Overview Historically, most patients with pancreatic cancer whose tumors grow outside the pancreas to encompass veins and arteries have been told that the cancer is inoperable and they should prepare for an average survival time of 12 to 18 months. Mayo Clinic surgical oncologists Mark J. Truty, M.D., M.S., and Chee-Chee H. Stucky, M.D., share the latest treatment innovations for pancreatic adenocarcinoma and explain how these innovations have extended survival. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleDevelopment of new surgical procedures and predictors of outcome for patients with advanced pancreatic cancer VID-20479495 Medical Professionals Treatment innovations for pancreatic adenocarcinoma